Ausgabe 4/2012
Inhalt (9 Artikel)
Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2
Motohiro Imano, Takao Satou, Tatsuki Itoh, Atsushi Yasuda, Hiroaki Kato, Masayuki Shinkai, Ying-Feng Peng, Masahiro Tsubaki, Takushi Yasuda, Haruhiko Imamoto, Shozo Nishida, Yoshifumi Takeyama, Kiyokata Okuno, Hitoshi Shiozaki
Anticancer role of MUC1 aptamer–miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation
Furong Dai, Yi Zhang, Xin Zhu, Nianchun Shan, Yuxiang Chen
Biosimilars and market access: a question of comparability and costs?
Steven Simoens, Gilbert Verbeken, Isabelle Huys
Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice
Maristella Saponara, Maria Abbondanza Pantaleo, Margherita Nannini, Guido Biasco
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma
Thomas Neuhaus, Joachim Luyken
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial
Christophe Le Tourneau, Maud Kamal, Olivier Trédan, Jean-Pierre Delord, Mario Campone, Anthony Goncalves, Nicolas Isambert, Thierry Conroy, David Gentien, Anne Vincent-Salomon, Anne-Lise Pouliquen, Nicolas Servant, Marc-Henri Stern, Anne-Gaëlle Le Corroller, Sébastien Armanet, Thomas Rio Frio, Xavier Paoletti
Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
Andrea Sartore-Bianchi, Katia Bencardino, Federica Di Nicolantonio, Federico Pozzi, Chiara Funaioli, Valentina Gambi, Sabrina Arena, Miriam Martini, Simona Lamba, Andrea Cassingena, Roberta Schiavo, Alberto Bardelli, Salvatore Siena